Press Releases

Sign up for Email Alerts Press Release RSS

06/04/2018
Opdivo (nivolumab) 3 mg/kg Demonstrates Sustained, Superior Recurrence-Free Survival Versus Yervoy (ipilimumab) 10 mg/kg for Broad Range of Patients with Resected Stage III or IV Melanoma
Term:Corporate/Financial News
Language:English
06/04/2018
Opdivo Plus Chemotherapy Showed Improved Progression-Free Survival Versus Chemotherapy in First-Line Lung Cancer Patients with PD-L1 <1%, in CheckMate -227 Study to Be Presented at ASCO 2018
Term:Corporate/Financial News
Language:English
06/02/2018
Preliminary Data for NKTR-214 in Combination with Opdivo (nivolumab) for Patients with Stage IV Metastatic Melanoma, Renal Cell Carcinoma, and Urothelial Cancers Presented at ASCO 2018
Term:
Language:English
06/01/2018
U.S. Food and Drug Administration Lifts Partial Clinical Hold on Opdivo (nivolumab)-based Combination Study in Multiple Myeloma
Term:Corporate/Financial News
Language:English
06/01/2018
Opdivo (nivolumab) Plus Low-Dose (1mg/kg) Yervoy (ipilimumab) Provided Significant and Sustained Health-Related Quality of Life Improvements in Intermediate- and Poor-Risk Patients with Advanced Renal Cell Carcinoma in CheckMate -214 Study
Term:Corporate/Financial News
Language:English
05/24/2018
Bristol-Myers Squibb to Hold Investor Event to Discuss ASCO Highlights
Term:Corporate/Financial News
Language:English
05/16/2018
Bristol-Myers Squibb Highlights Breadth of Immuno-Oncology–Based Combination Research and Commitment to Advancing Precision Medicine at ASCO 2018
Term:Corporate/Financial News
Language:English
05/15/2018
Bristol-Myers Squibb to Take Part in UBS 2018 Global Healthcare Conference
Term:Corporate/Financial News
Language:English
05/03/2018
European Medicines Agency Validates Bristol-Myers Squibb’s Type II Variation Application for Opdivo Plus Yervoy Combination for Treatment of First-Line Metastatic Non-Small Cell Lung Cancer (NSCLC)
Term:Corporate/Financial News
Language:English
05/02/2018
Bristol-Myers Squibb and Flatiron Health Expand Collaboration with a Three-Year Agreement
Term:Partnering News
Language:English

Business Wire NewsHQ^sm